Current Neuro-Oncology




Volume 28 Number 25
30 September 2026




Home > Publications > Current Neuro-Oncology > Volume 28, Year 2026 > Number 25, 30 September






Ruggiero A, Attinà G, Placidi G, D'Agostino E, Amato A, Verdolotti T, Mastrangelo S, Falsini B.
Long-term outcomes after a randomized phase II trial of nerve growth factor eye drops for optic pathway gliomas: four-year follow-up findings in children.
J Neurooncol. 2026 Sep 1;179(2):67. doi: 10.1007/s11060-026-05777-z. PMID: 42681266. Trial registration ID: NCT05733572. ˍ




Jackson JS, Schaffer DH, Harris LJ.
Nitrosoureas Toxicity.
StatPearls Publishing. 2026 Sep 8. Bookshelf ID: NBK599513 PMID: 38261709. ˍ




Liu J, Wu P, Li D, Gu X, Zhao B, Ma R, Tan B, Shang D, Wu Y, Zhou J, Lin C, Sun N, Zhang C, He J.
Efficacy of immune checkpoint inhibitors in female patients with cancer: a systematic review and meta-analysis.
Sci China Life Sci. 2026 Sep 15. doi: 10.1007/s11427-025-3225-1. PMID: 42752777˰ ˍ




Chen L, Gao Y, Zhong J, Zhang N.
Beyond the tumour microenvironment: Harnessing border immunity for glioblastoma immunotherapy.
Clin Transl Med. 2026 Sep 18;16(9):e70841. doi: 10.1002/ctm2.70841. PMID: 42755438. ˍ




Ghoche MT, Miki K, Yuan F, Mantica M, Agnihotri S, McBrayer SK, Abdullah KG.
Metabolic modulation of glioblastoma by dietary intervention: a systematic review.
J Neurooncol. 2026 Sep 18;179(3):90. doi: 10.1007/s11060-026-05779-x. PMID: 42758370˰ ˍ




Sravya P, Altay LN, Do K, Freeman J, Gokul A, Liang N, Scott AJ, Xu J, Korimerla N, Lin A, Wang H, Wilder-Romans K, Singer A, O'Brien A, Animasahun O, Meghdadi B, Baker E, Peterson ER, McCulla EC, Zhu Z, Thomas D, Andren A, Wong H, Sajjakulnukit P, Zhang L, Shankar S, Ravikumar V, Lee ZH, Carrion JAN, Bhadury S, Miller CR, Sarkaria JN, Heth JA, Huse JT, Camelo-Piragua S, Morgan MA, Lawrence TS, Rao A, Lyssiotis C, Al-Holou W, Nagrath D, Zhou W, Wahl DR.
Microenvironment-derived acetylated amino acids promote glioblastoma treatment resistance.
Res Sq [Preprint]. 2026 Sep 18:rs.3.rs-10976328. doi: 10.21203/rs.3.rs-10976328/v1. PMID: 42780293. ˍ


Annotation:
The role of non-malignant cell types in the tumor microenvironment in accelerating DNA repair in neoplastic cells




Wang L, Ding J, Liu X, Li T, Liu Y, You Y, Yu Y, Zheng Y.
Safety and efficacy of sonodynamic therapy combined with Stupp regimen in controlling postoperative residual lesions of glioblastoma: A prospective pilot phase I study.
Photodiagnosis Photodyn Ther. 2026 Sep 18;61:105655. doi: 10.1016/j.pdpdt.2026.105655. PMID: 42759826. Trial Ethics Approval No 2024-KY-0621–002. ˍ




Nicolaides T, Hoogendijk R, Jaeger-Krause M, Dhall G, Goldman S, Gajjar A, Kilburn L, Leary S, Minturn J, Whipple N, Ramakrishnan D, Long-Boyle J, Aboian M, Prados M, Molinaro AM, Mueller S.
Efficacy Study of Vemurafenib in Children With Recurrent or Progressive BRAFV600E- or BRAFInsT-Mutant Brain Tumors: PNOC002.
JCO Precis Oncol. 2026 Sep 23;10(9):e2600558. doi: 10.1200/PO-26-00558. PMID: 42777179. Trial registration ID: PNOC002. ˍ




Zadeh SMM, Kalantari S, Dastgerdi SS, Sharifi H, Mohammadi M, Roudi R, Shariftabrizi A, Kalantari A, Ahmadvand D, Yazdi M, Nedaeinia R.
Efficacy of CAR-T-Cell-Based Immunotherapies in Patients With Glioma: A Systematic Review and Meta-Analysis.
J Cell Mol Med. 2026 Sep 25;30(18):e71358. doi: 10.1111/jcmm.71358. PMID: 42791198. ˍ




Costa Filho VO, Rabenhorst SHB, Mesquita FP.
Next-generation CAR-T therapy for malignant brain tumors: latest updates from the 2026 AACR Annual Meeting.
Exp Hematol Oncol. 2026 Sep 28;15(1):101. doi: 10.1186/s40164-026-00834-9. PMID: 42806401. ˍ